Furthermore, ERK1/2 inhibition reduced CD44(+) HNSCC cell migration and invasion by 75.4–92.3% and 80.1–87.5%, respectively (Fig. 4g). This evidence concerns the gene CD44 and head and neck squamous cell carcinoma.